Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...
June 02, 2022 20:10 ET | Source: Aptose Biosciences, Inc.

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
June 02, 2022 17:30 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
May 27, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Hold Corporate Update Friday, June 11th

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual...
March 23, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Fourth Quarter and Full Year 2020

- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...